Global Blood Therapeutics
NEWS
Global Blood Therapeutics was acquired by Pfizer in August 2022.
The following features are highlights from the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, held in-person in Atlanta, GA, and virtually from December 11 to 14.
The Biotech Bay region is home to 3,418 life sciences companies and 96,574 employees making an average of $148,285. Here’s a look at a few of the bay area biotech companies hiring now.
The results published in the NEJM state that pegcetacoplan met the study’s primary endpoint for efficacy, demonstrating an advantage over eculizumab with a statistically significant improvement in adjusted means of 3.8 g/dL of hemoglobin at week 16 (p<0.001). An impressive 85% of patients were transfusion free at 16 weeks, in contrast to only 15% of eculizumab-treated patients.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Biopharma and life science companies and organizations strengthen their leadership teams and boards with these Movers & Shakers.
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
Here’s a look at the two drugs that had dates this week but were approved early and are now on the market.
Less than a month after snagging approval for a first-of-its-kind sickle cell disease treatment, Global Blood Therapeutics (GBT) is already looking at next-generation measures to tackle the disorder, as well as other diseases of the blood such as beta thalassemia.
JOBS
IN THE PRESS